Aberrant Gene Expression Prostate Carcinoma
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Linda Topjian, Lahey Clinic
First received: March 24, 2009
Last updated: March 30, 2015
Last verified: March 2015
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
||Time Perspective: Prospective
||Identification of Aberant Gene Expression in Human Prostatic Carcinoma
Biospecimen Retention: Samples With DNA
Surplus tissue following pathologic review requirements will be snap frozen and processed for extraction of RNA. mRNA will be reversed transcribed to make cDNA with the prime 5'TCCTTAGAAC, followed by 40 cycles of palindromic PCR using the sam eprimer. Amplified cDNA (35 S-labled) will be analysed on a 4% polyacrylamide gel. Comparative analysis of cDNA amplified products will serve to identify aberrantly expressed candidate genes. Such products will be isolated, sequenced and evaluated as to their role in establishing the neoplastic pheotype and the potential utility as a marker of prostatic neoplastic progression.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||April 2020 (Final data collection date for primary outcome measure)
The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostatic cancer, using established molecular genetic approaches, and extend these studies to sporadic prostatic cancer using a novel technique of differential display. Application of the latter technique to colon cancer in the American population establishes this tumor type as a high priority for scientific investigation and this study is part of an initiative to address this problem. Presently the studies in the field of prostate are under-represented. The collection of tissue samples from patients diagnosed with prostate cancer. Patients will also provide a blood sample at the time of their surgery and potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following the biopsy out to 6 months after the biopsy.
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
patients diagnosed with prostate cancer patients undergoing surgery for suspected prostate cancer but have negative biopsy healthy volunteers - blood sample only
- Diagnosed prostate cancer undergoing prostatectomy
- Suspicion of prostate cancer undergoing biopsy - negative biopsy
- Health volunteer (control group) - blood sample for PSA
- Patients not fitting the inclusion criteria
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00868803
|Burlington, Massachusetts, United States, 01805 |
||John A Libertino, M.D.
No publications provided
||Linda Topjian, study coordinator, Lahey Clinic
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 24, 2009
||March 30, 2015
||United States: Institutional Review Board
Keywords provided by Lahey Clinic:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site